ANI Pharmaceuticals, Inc. (ANIP)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 4:00 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow ANIP in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on ANIP and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
ANIP at a glance
Key statistics
$1.67B
Market capitalization
- Previous close
- $72.67
- Open
- $72.44
- Day range
- $71.80 – $73.51
- Volume
- 345.0K
- Average volume (30 sessions)
- 396.2K
- Shares outstanding
- 22.96M
- Price / earnings
- 16.8
- Earnings per share
- $4.34
- Price / book
- 2.8
- Price / sales
- 1.7
- Dividend yield
- 0.02%
- Beta (1 year, vs SPY)
- 0.27
Where the price sits in its year
52-week range
10% of the range
- Below the 52-week high
- -25.5%
- Above the 52-week low
- +3.8%
Completed sessions through Oct 21, 2026
Technical snapshot
Below its 50-day and 200-day averages
- 20-day average
- $72.59-0.5%
- 50-day average
- $73.51-1.7%
- 200-day average
- $77.95-7.3%
Between the conventional 30 and 70 bands.
+3.0%
1 week
-7.3%
1 month
-8.0%
3 months
-8.5%
Year to date
-24.1%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with ANIP
ANIP on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on ANIP.
See the plans →
Every planScreen names like ANIP
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on ANIP
Put ANIP on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on ANIP
See whether there is an open premium alert on ANIP, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
ANIP headlines
- ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
GlobeNewswire Inc. · Jul 24, 2026
- ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis
GlobeNewswire Inc. · Jul 13, 2026
- ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
GlobeNewswire Inc. · Feb 13, 2026
- ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
GlobeNewswire Inc. · May 12, 2025
- ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast
Benzinga · Feb 28, 2025
- ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET
GlobeNewswire Inc. · Oct 30, 2024
- ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
Benzinga · Sep 16, 2024
- ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
Benzinga · Sep 11, 2024
SEC Form 4, most recent first
Insider filings
Lalwani Nikhil
−5.4K
PRESIDENT & CEO, Director · Open-market sale
$388.21K · Oct 15, 2026
Cook Meredith
−500
SR. VP, GENERAL COUNSEL & SEC. · Open-market sale
$36.80K · Oct 13, 2026
CAREY STEPHEN P.
−2.9K
SVP & CFO · Open-market sale
$208.05K · Sep 29, 2026
Lalwani Nikhil
−5.4K
PRESIDENT & CEO, Director · Open-market sale
$383.40K · Sep 15, 2026
Cook Meredith
−500
SR. VP, GENERAL COUNSEL & SEC. · Open-market sale
$35.40K · Sep 14, 2026
Thoma Jeanne
−1.0K
Director · Open-market sale
$71.53K · Sep 11, 2026
CAREY STEPHEN P.
−2.9K
SVP & CFO · Open-market sale
$207.48K · Aug 31, 2026
Gosebruch Henry O
+6.7K
Director · Grant or award
· Aug 19, 2026
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Princeton, NJ
- Employees
- 970
- Listed since
- Sep 13, 1999
- Website
- anipharmaceuticals.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.